NASDAQ:AZN - Nasdaq - US0463531089 - ADR - Currency: USD
We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 197 industry peers in the Pharmaceuticals industry. While AZN belongs to the best of the industry regarding profitability, there are concerns on its financial health. AZN scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.31% | ||
ROE | 18.94% | ||
ROIC | 14.1% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 24.05% | ||
PM (TTM) | 14.14% | ||
GM | 82.36% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.71 | ||
Debt/FCF | 3.46 | ||
Altman-Z | 2.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.9 | ||
Quick Ratio | 0.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 16.03 | ||
Fwd PE | 13.38 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 23.93 | ||
EV/EBITDA | 12.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.34% |
NASDAQ:AZN (5/29/2025, 9:54:09 AM)
70.53
+0.15 (+0.21%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.34% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 16.03 | ||
Fwd PE | 13.38 | ||
P/S | 3.98 | ||
P/FCF | 23.93 | ||
P/OCF | 16.71 | ||
P/B | 5.33 | ||
P/tB | N/A | ||
EV/EBITDA | 12.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 7.31% | ||
ROE | 18.94% | ||
ROCE | 17.15% | ||
ROIC | 14.1% | ||
ROICexc | 15.14% | ||
ROICexgc | 76.66% | ||
OM | 24.05% | ||
PM (TTM) | 14.14% | ||
GM | 82.36% | ||
FCFM | 16.62% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.71 | ||
Debt/FCF | 3.46 | ||
Debt/EBITDA | 1.47 | ||
Cap/Depr | 58.81% | ||
Cap/Sales | 7.18% | ||
Interest Coverage | 9.49 | ||
Cash Conversion | 65.63% | ||
Profit Quality | 117.58% | ||
Current Ratio | 0.9 | ||
Quick Ratio | 0.7 | ||
Altman-Z | 2.97 |